(UroToday.com) Prior randomized controlled trials have demonstrated that the use of blue light cystoscopy (BLC) is associated with improved detection of both carcinoma-in-situ and papillary bladder tumors. As a result, BLC is recommended for use in patients with a history of non-muscle-invasive bladder cancer (NMIBC) undergoing surveillance or treatment cystoscopy. However, BLC is associated with a meaningful false positive rate of up to 30%. Many of these false-positive findings may be attributable to a variety of benign inflammatory and/or infectious bladder conditions. Thes conditions may be more common in women. To evaluate further the effect of gender on BLC performance, in a moderated poster presentation at the American Urological Association (AUA) 2020 Virtual Meeting, Ashley Alford, MD, and colleagues report on their analysis of the Cysview® registry to examine differences in the false-positive rate and overall sensitivity of BLC between genders.